Atrial Fibrillation and Heart Failure in the Aging Population

Chapter

Abstract

Atrial fibrillation (AF) is a common condition affecting more than 2.2 million Americans, and nearly ¾ of all patients with AF are over 65. It is a major risk factor for serious cardiovascular events, such as stroke, heart failure (HF) and premature death. Aging-related atrial remodelling with fibrosis, dilation and mitochondrial DNA mutations predisposes elderly patients to AF. New therapeutic modalities including novel anticoagulation medications, antiarrhythmic drugs (AADs) and catheter-based ablation (CBA) have significantly impacted our approach to management of AF and are of particular interest for the elderly although they have not been extensively studied in this group of patients.

This chapter will review the epidemiology, pathophysiology and management options for AF and discuss the role of new advances in management of AF in the elderly.

Keywords

Atrial Fibrillation Atrial Fibrillation Patient Pulmonary Vein Isolation Heart Failure With Preserve Ejection Fraction Prothrombin Complex Concentrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–61.PubMedGoogle Scholar
  2. 2.
    Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–73.PubMedGoogle Scholar
  3. 3.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–215.PubMedGoogle Scholar
  4. 4.
    Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005;14(2):56–61.PubMedGoogle Scholar
  5. 5.
    Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25. doi: 10.1161/CIRCULATIO-NAHA.105.595140. [pii]: CIRCULATIONAHA.105.595140.PubMedGoogle Scholar
  6. 6.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–5. [pii]: jcc10004.PubMedGoogle Scholar
  7. 7.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–8.PubMedGoogle Scholar
  8. 8.
    Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med. 1989;19(4):321–6.PubMedGoogle Scholar
  9. 9.
    Phillips SJ, Whisnant JP, O’Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc. 1990;65(3):344–59.PubMedGoogle Scholar
  10. 10.
    Langenberg M, Hellemons BS, van Ree JW, Vermeer F, Lodder J, Schouten HJ, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ. 1996;313(7071):1534.PubMedGoogle Scholar
  11. 11.
    Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53. doi: 10.1093/eurheartj/ehi825. [pii]: ehi825.PubMedGoogle Scholar
  12. 12.
    Wolk R, Kulakowski P, Karczmarewicz S, Karpinski G, Makowska E, Czepiel A, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol. 1996;54(3):207–11. [pii]: 0167527396026319.PubMedGoogle Scholar
  13. 13.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9.PubMedGoogle Scholar
  14. 14.
    de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725–31. doi: 10.1016/j.jacc.2009.11.040.PubMedGoogle Scholar
  15. 15.
    Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82(8A):10N–7.PubMedGoogle Scholar
  16. 16.
    Lai LP, Tsai CC, Su MJ, Lin JL, Chen YS, Tseng YZ, et al. Atrial fibrillation is associated with accumulation of aging-related common type mitochondrial DNA deletion mutation in human atrial tissue. Chest. 2003;123(2):539–44.PubMedGoogle Scholar
  17. 17.
    Manyari DE, Patterson C, Johnson D, Melendez L, Kostuk WJ, Cape RD. Atrial and ventricular arrhythmias in asymptomatic active elderly subjects: correlation with left atrial size and left ventricular mass. Am Heart J. 1990;119(5):1069–76.PubMedGoogle Scholar
  18. 18.
    Pan NH, Tsao HM, Chang NC, Chen YJ, Chen SA, Pan N-H, et al. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest. 2008;133(1):190–6.PubMedGoogle Scholar
  19. 19.
    Centurión OA, Isomoto S, Shimizu A, Konoe A, Kaibara M, Hirata T, et al. The effects of aging on atrial endocardial electrograms in patients with paroxysmal atrial fibrillation. Clin Cardiol. 2003;26(9):435–8.PubMedGoogle Scholar
  20. 20.
    Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995;98(5):476–84. doi: 10.1016/S0002-9343(99)80348-9. [pii]: S0002-9343(99)80348-9.PubMedGoogle Scholar
  21. 21.
    Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996;27(10):1760–4.PubMedGoogle Scholar
  22. 22.
    Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10(1):39–43. 16023.PubMedGoogle Scholar
  23. 23.
    Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–9. doi: 10.1056/NEJMoa1105575.PubMedGoogle Scholar
  24. 24.
    Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8(9):1416–23. doi: 10.1016/j.hrthm.2011.04.022.PubMedGoogle Scholar
  25. 25.
    Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7(4):433–7.PubMedGoogle Scholar
  26. 26.
    Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. Circulation. 1995;92(8):2178–82.PubMedGoogle Scholar
  27. 27.
    Lavy S, Stern S, Melamed E, Cooper G, Keren A, Levy P. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke. 1980;11(1):35–8.PubMedGoogle Scholar
  28. 28.
    Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, et al. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol. 2009;32(5):648–52. doi: 10.1111/j.1540-8159.2009.02339.x.PubMedGoogle Scholar
  29. 29.
    Jugdutt BI. Heart failure in the elderly: advances and challenges. Expert Rev Cardiovasc Ther. 2010;8(5):695–715. doi: 10.1586/erc.10.36.PubMedGoogle Scholar
  30. 30.
    Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;32(3):695–703. [pii]: S0735109798002976.PubMedGoogle Scholar
  31. 31.
    Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6A):2D–8D. [pii]: S0002914902033738.PubMedGoogle Scholar
  32. 32.
    Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84(1):40–8.PubMedGoogle Scholar
  33. 33.
    Linderer T, Chatterjee K, Parmley WW, Sievers RE, Glantz SA, Tyberg JV. Influence of atrial systole on the Frank–Starling relation and the end-diastolic pressure–diameter relation of the left ventricle. Circulation. 1983;67(5):1045–53.PubMedGoogle Scholar
  34. 34.
    Keren G, Bier A, Sherez J, Miura D, Keefe D, LeJemtel T. Atrial contraction is an important determinant of pulmonary venous flow. J Am Coll Cardiol. 1986;7(3):693–5.PubMedGoogle Scholar
  35. 35.
    Jugdutt BI, Jelani A. Aging and defective healing, adverse remodeling, and blunted post-conditioning in the reperfused wounded heart. J Am Coll Cardiol. 2008;51(14):1399–403. doi: 10.1016/j.jacc.2007.12.027. [pii]: S0735-1097(08)00321-5.PubMedGoogle Scholar
  36. 36.
    Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32(1):197–204. [pii]: S0735-1097(98)00221-6.PubMedGoogle Scholar
  37. 37.
    Moe GW, Stopps TP, Angus C, Forster C, De Bold AJ, Armstrong PW. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J Am Coll Cardiol. 1989;13(1):173–9. [pii]: 0735-1097(89)90567-6.PubMedGoogle Scholar
  38. 38.
    Moe GW, Grima EA, Wong NL, Howard RJ, Armstrong PW. Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. J Am Coll Cardiol. 1996;27(3):720–7. [pii]: 0735-1097(95)00504-8.PubMedGoogle Scholar
  39. 39.
    Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res. 1999;42(3):591–9. [pii]: S0008636399000322.PubMedGoogle Scholar
  40. 40.
    Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol. 1995;268(6 Pt 2):H2426–39.PubMedGoogle Scholar
  41. 41.
    Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PD. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol. 1996;28(8):1591–608. doi: 10.1006/jmcc.1996.0150.PubMedGoogle Scholar
  42. 42.
    Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82(4):482–95.PubMedGoogle Scholar
  43. 43.
    Kohno M, Horio T, Toda I, Akioka K, Tahara A, Teragaki M, et al. Cosecretion of atrial and brain natriuretic peptides during supraventricular tachyarrhythmias. Am Heart J. 1992;123(5):1382–4. [pii]: 0002-8703(92)91049-7.PubMedGoogle Scholar
  44. 44.
    Everett TH, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation. 2000;102(12):1454–60.PubMedGoogle Scholar
  45. 45.
    Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation. 1996;94(7):1600–6.PubMedGoogle Scholar
  46. 46.
    Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802–9. doi: 10.1016/j.jacc.2007.09.064. [pii]: S0735-1097(07)03786-2.PubMedGoogle Scholar
  47. 47.
    Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100(1):87–95.PubMedGoogle Scholar
  48. 48.
    Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101(22):2631–8.PubMedGoogle Scholar
  49. 49.
    Lin CS, Lai LP, Lin JL, Sun YL, Hsu CW, Chen CL, et al. Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation. Heart Rhythm. 2007;4(7):938–49. doi: 10.1016/j.hrthm.2007.03.034. [pii]: S1547-5271(07)00317-7.PubMedGoogle Scholar
  50. 50.
    Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett. 2007;581(3):526–34. doi: 10.1016/j.febslet.2007.01.014. [pii]: S0014-5793(07)00040-3.PubMedGoogle Scholar
  51. 51.
    Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104(21):2608–14.PubMedGoogle Scholar
  52. 52.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation. 2009;119(14):e391–479. doi: 10.1161/CIRCULATIONAHA.109.192065. [pii]: CIRCULATIONAHA.109.192065.PubMedGoogle Scholar
  53. 53.
    Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202. [pii]: joc21616.PubMedGoogle Scholar
  54. 54.
    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation. 2002;105(12):1503–8.PubMedGoogle Scholar
  55. 55.
    Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636–44. [pii]: S0735109702023732.PubMedGoogle Scholar
  56. 56.
    Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7(9):833–42.PubMedGoogle Scholar
  57. 57.
    Knackstedt C, Gramley F, Schimpf T, Mischke K, Zarse M, Plisiene J, et al. Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc Pathol. 2008;17(5):318–24. doi: 10.1016/j.carpath.2007.12.003. [pii]: S1054-8807(07)00203-7.PubMedGoogle Scholar
  58. 58.
    Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35(6):1669–77. [pii]: S0735-1097(00)00611-2.PubMedGoogle Scholar
  59. 59.
    Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108(11):1395–403. doi: 10.1161/01.CIR.0000085658.98621.49. [pii]: 108/11/1395.PubMedGoogle Scholar
  60. 60.
    Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3(1):1–30.PubMedGoogle Scholar
  61. 61.
    Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21):2299–307. doi: 10.1016/j.jacc.2010.01.043. [pii]: S0735-1097(10)01089-2.PubMedGoogle Scholar
  62. 62.
    Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832–9. doi: 10.1016/j.jacc.2004.11.070.PubMedGoogle Scholar
  63. 63.
    Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15(1):36–43. doi: 10.1097/MJT.0b013e31804beb59.PubMedGoogle Scholar
  64. 64.
    Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg. 2012;147(2):181–9. doi: 10.1001/archsurg.2011.897.PubMedGoogle Scholar
  65. 65.
    Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011;124(10):1107–17. doi: 10.1161/CIRCULATION-AHA.111.029223.PubMedGoogle Scholar
  66. 66.
    Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126(2):160–70. doi: 10.1016/j.ijcard.2007.07.137.PubMedGoogle Scholar
  67. 67.
    Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342:d1250. doi: 10.1136/bmj.d1250.PubMedGoogle Scholar
  68. 68.
    ClinicalTrials.gov. Search for: statins and atrial fibrillation. Last Accessed on February 7th, 2013. http://clinicaltrials.gov/ct2/results?term=statins+and+atrial+fibrillation&no_unk=Y Google Scholar
  69. 69.
    Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116(19):2101–9. doi: 10.1161/CIRCULATIONAHA.107.704759. [pii]: CIRCULATIONAHA.107.704759.PubMedGoogle Scholar
  70. 70.
    Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010. doi: 10.1001/jama.2010.1735. [pii]: jama.2010.1735.PubMedGoogle Scholar
  71. 71.
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation––pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789–94. [pii]: S014067360003230X.PubMedGoogle Scholar
  72. 72.
    Hohnloser SH, Kuck KH. Randomized trial of rhythm or rate control in atrial fibrillation: the pharmacological intervention in atrial fibrillation trial (PIAF). Eur Heart J. 2001;22(10):801–2. doi: 10.1053/euhj.2001.2596. [pii]: S0195668X01925965.PubMedGoogle Scholar
  73. 73.
    Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J. 2003;24(15):1430–6. [pii]: S0195668X03002616.PubMedGoogle Scholar
  74. 74.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33. doi: 10.1056/NEJMoa021328. [pii]: 347/23/1825.PubMedGoogle Scholar
  75. 75.
    Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40. doi: 10.1056/NEJMoa021375. [pii]: 347/23/1834.PubMedGoogle Scholar
  76. 76.
    Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–6. [pii]: S0735109703003322.PubMedGoogle Scholar
  77. 77.
    Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest. 2004;126(2):476–86. doi: 10.1378/chest.126.2.476. [pii]: 126/2/476.PubMedGoogle Scholar
  78. 78.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–77. doi: 10.1056/NEJMoa0708789. [pii]: 358/25/2667.PubMedGoogle Scholar
  79. 79.
    Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M, et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;55(17):1796–802. doi: 10.1016/j.jacc.2010.01.023. [pii]: S0735-1097(10)00686-8.PubMedGoogle Scholar
  80. 80.
    de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165(3):258–62. doi: 10.1001/archinte.165.3.258. [pii]: 165/3/258.PubMedGoogle Scholar
  81. 81.
    Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II study). Heart. 2009;95(11):924–30. doi: 10.1136/hrt.2008.158931. [pii]: hrt.2008.158931.PubMedGoogle Scholar
  82. 82.
    Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82(4):1106–16.PubMedGoogle Scholar
  83. 83.
    Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol. 1992;20(3):527–32.PubMedGoogle Scholar
  84. 84.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25(16):1385–94. doi: 10.1016/j.ehj.2004.04.015.PubMedGoogle Scholar
  85. 85.
    Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, et al. Suppression of paroxysmal atrial tachyarrhythmias––results of the SOPAT trial. Eur Heart J. 2004;25(16):1395–404. doi: 10.1016/j.ehj.2004.06.014.PubMedGoogle Scholar
  86. 86.
    Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (the European rythmol/rytmonorm atrial fibrillation trial [ERAFT] study). Am J Cardiol. 2002;90(12):1300–6. [pii]: S0002914902028679.PubMedGoogle Scholar
  87. 87.
    Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide supraventricular tachycardia study group. Circulation. 1989;80(6):1557–70.PubMedGoogle Scholar
  88. 88.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12):781–8.PubMedGoogle Scholar
  89. 89.
    Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993;270(13):1589–95.PubMedGoogle Scholar
  90. 90.
    Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST investigators. J Am Geriatr Soc. 1992;40(7):666–72.PubMedGoogle Scholar
  91. 91.
    Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med. 1997;337(25):1785–91.PubMedGoogle Scholar
  92. 92.
    Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med. 2000;342(13):913–20.PubMedGoogle Scholar
  93. 93.
    Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76(1):47–50. [pii]: S0002914999807991.PubMedGoogle Scholar
  94. 94.
    Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial fibrillation suppression trial (AFIST): a randomised placebo-controlled trial. Lancet. 2001;357(9259):830–6. doi: 10.1016/S0140-6736(00)04196-9. [pii]: S0140-6736(00)04196-9.PubMedGoogle Scholar
  95. 95.
    Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol. 2003;41(2):249–54. [pii]: S0735109702027092.PubMedGoogle Scholar
  96. 96.
    Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791–8. [pii]: S0735-1097(97)00220-9.PubMedGoogle Scholar
  97. 97.
    Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol. 1990;65(2):74A–81A. discussion 82A–83A.PubMedGoogle Scholar
  98. 98.
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European heart rhythm association and the heart rhythm society. Europace. 2006;8(9):651–745. doi: 10.1093/europace/eul097. [pii]: 8/9/651.PubMedGoogle Scholar
  99. 99.
    Lehmann MH, Hardy S, Archibald D, MacNeil DJ. JTc prolongation with d, l-sotalol in women versus men. Am J Cardiol. 1999;83(3):354–9.PubMedGoogle Scholar
  100. 100.
    Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation. 1996;94(10):2535–41.PubMedGoogle Scholar
  101. 101.
    Deneer VH, van Hemel NM. Is antiarrhythmic treatment in the elderly different? A review of the specific changes. Drugs Aging. 2011;28(8):617–33. doi: 10.2165/11591680-000000000-00000.PubMedGoogle Scholar
  102. 102.
    Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21(15):1265–73. doi: 10.1053/euhj.1999.2039. [pii]: S0195668X99920390.PubMedGoogle Scholar
  103. 103.
    Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31(6):1414–9. [pii]: S0735-1097(98)00078-3.PubMedGoogle Scholar
  104. 104.
    Moller M, Torp-Pedersen CT, Kober L. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish investigators of arrhythmia and mortality on dofetilide (DIAMOND) study group. Congest Heart Fail. 2001;7(3):146–50.PubMedGoogle Scholar
  105. 105.
    Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002;39(5):677–84.PubMedGoogle Scholar
  106. 106.
    Cheng JW. New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation. Am J Health Syst Pharm. 2010;67(9 Suppl 5):S26–34. doi: 10.2146/ajhp100154. [pii]: 67/9_Supplement_5/S26.PubMedGoogle Scholar
  107. 107.
    Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009;120(7):636–44. doi: 10.1161/CIRCULATIONAHA.109.858027. [pii]: 120/7/636.PubMedGoogle Scholar
  108. 108.
    Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987–99. doi: 10.1056/NEJMoa054686. [pii]: 357/10/987.PubMedGoogle Scholar
  109. 109.
    Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87. doi: 10.1056/NEJMoa0800456. [pii]: 358/25/2678.PubMedGoogle Scholar
  110. 110.
    Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–78. doi: 10.1056/NEJMoa0803778. [pii]: 360/7/668.PubMedGoogle Scholar
  111. 111.
    Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597–605. doi: 10.1111/j.1540-8167.2010.01764.x. [pii]: JCE1764.PubMedGoogle Scholar
  112. 112.
    Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76. doi: 10.1056/NEJMoa1109867.PubMedGoogle Scholar
  113. 113.
    Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes 3rd NA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2011;123(1):104–23. doi: 10.1161/CIR.0b013e3181fa3cf4. [pii]: CIR.0b013e3181fa3cf4.PubMedGoogle Scholar
  114. 114.
    Williams BR, Kim J. Cardiovascular drug therapy in the elderly: theoretical and practical considerations. Drugs Aging. 2003;20(6):445–63. [pii]: 2064.PubMedGoogle Scholar
  115. 115.
    Vadiei K, Troy S, Korth-Bradley J, Chiang ST, Zimmerman JJ. Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol. 1997;37(7):610–7.PubMedGoogle Scholar
  116. 116.
    Hamer A, Peter T, Mandel WJ, Scheinman MM, Weiss D. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982;65(5):1025–9.PubMedGoogle Scholar
  117. 117.
    Tsang P, Gerson B. Understanding digoxin use in the elderly patient. Clin Lab Med. 1990;10(3):479–92.PubMedGoogle Scholar
  118. 118.
    Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–37. doi: 10.1016/j.jacc.2010.05.028. [pii]: S0735-1097(10)02415-0.PubMedGoogle Scholar
  119. 119.
    van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410–6. doi: 10.1161/STROKEAHA.108.526988.PubMedGoogle Scholar
  120. 120.
    Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994:154 (13):1449–57Google Scholar
  121. 121.
    Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I–III clinical trials. The stroke prevention in atrial fibrillation (SPAF) investigators. Stroke. 1999;30(6):1223–9.PubMedGoogle Scholar
  122. 122.
    Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–92. doi: 10.1161/01.CIR.0000145172.55640.93. [pii]: 01.CIR.0000145172.55640.93.PubMedGoogle Scholar
  123. 123.
    Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost. 2009;101(5):802–5. [pii]: 09050802.PubMedGoogle Scholar
  124. 124.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. doi: 10.1378/chest.09-1584. [pii]: chest.09-1584.PubMedGoogle Scholar
  125. 125.
    Hylek EM. Contra: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost. 2008;100(1):16–7. doi: 10.1160/TH08-06-0343. [pii]: 08070016.PubMedGoogle Scholar
  126. 126.
    Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005;165(13):1527–32. doi: 10.1001/archinte.165.13.1527.PubMedGoogle Scholar
  127. 127.
    Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700–5. doi: 10.1016/j.amjmed.2006.07.034.PubMedCentralPubMedGoogle Scholar
  128. 128.
    Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. doi: 10.1016/j.ahj.2005.04.017.PubMedGoogle Scholar
  129. 129.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol. 2011;58(4):395–401. doi: 10.1016/j.jacc.2011.03.031.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro heart survey. Chest. 2010. doi: 10.1378/chest.10-0134. chest.10-0134 [pii].Google Scholar
  131. 131.
    van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–8. [pii]: doi:jcc20007.PubMedGoogle Scholar
  132. 132.
    Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12. doi: 10.1016/S0140-6736(06)68845-4. [pii]: S0140-6736(06)68845-4.PubMedGoogle Scholar
  133. 133.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27. doi: 10.1160/TH09-11-0758.PubMedGoogle Scholar
  134. 134.
    Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59. [pii]: 4715.PubMedGoogle Scholar
  135. 135.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. doi: 10.1056/NEJMoa0905561. [pii]: NEJMoa0905561.PubMedGoogle Scholar
  136. 136.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72. doi: 10.1161/CIRCULA-TIONAHA.110.004747.PubMedGoogle Scholar
  137. 137.
    Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125–36. doi: 10.1016/j.cjca.2012.01.021.PubMedGoogle Scholar
  138. 138.
    De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol. 2012;59(16):1413–25. doi: 10.1016/j.jacc.2012.02.008.PubMedGoogle Scholar
  139. 139.
    Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138–43. doi: 10.1097/MBC.0b013e32834f1b0c.PubMedGoogle Scholar
  140. 140.
    Samama MM. The mechanism of action of rivaroxaban––an oral, direct Factor Xa inhibitor––compared with other anticoagulants. Thromb Res. 2011;127(6):497–504. doi: 10.1016/j.thromres.2010.09.008.PubMedGoogle Scholar
  141. 141.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. doi: 10.1056/NEJMoa1009638.PubMedGoogle Scholar
  142. 142.
    Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs. 2008;17(12):1937–45. doi: 10.1517/13543780802528625.PubMedGoogle Scholar
  143. 143.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. doi: 10.1056/NEJMoa1107039.PubMedGoogle Scholar
  144. 144.
    Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. doi: 10.1056/NEJMoa1007432.PubMedGoogle Scholar
  145. 145.
    Lahaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J. 2012;33(17):2163–71. doi: 10.1093/eurheartj/ehs167.PubMedGoogle Scholar
  146. 146.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9. doi: 10.1161/CIRCULA-TIONAHA.111.029017.PubMedGoogle Scholar
  147. 147.
    Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141–5. doi: 10.1002/ajh.23202.PubMedGoogle Scholar
  148. 148.
    Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electro-physiol. 2012;33(2):171–257. doi: 10.1007/s10840-012-9672-7.Google Scholar
  149. 149.
    Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2(4):349–61. doi: 10.1161/CIRCEP.108.824789. [pii]: CIRCEP.108.824789.PubMedGoogle Scholar
  150. 150.
    Zado E, Callans DJ, Riley M, Hutchinson M, Garcia F, Bala R, et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol. 2008;19(6):621–6. doi: 10.1111/j.1540-8167.2008.01183.x.PubMedGoogle Scholar
  151. 151.
    Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351(23):2373–83. doi: 10.1056/NEJMoa041018. [pii]: 351/23/2373.PubMedGoogle Scholar
  152. 152.
    Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333–40.PubMedGoogle Scholar
  153. 153.
    Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74. doi: 10.1016/j.jacc.2011.12.014.PubMedGoogle Scholar
  154. 154.
    Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace. 2007;9(7):498–505. doi: 10.1093/europace/eum091. [pii]: eum091.PubMedGoogle Scholar
  155. 155.
    Kay GN, Ellenbogen KA, Giudici M, Redfield MM, Jenkins LS, Mianulli M, et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol. 1998;2(2):121–35.PubMedGoogle Scholar
  156. 156.
    Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101(10):1138–44.PubMedGoogle Scholar
  157. 157.
    Leong DP, Mitchell AM, Salna I, Brooks AG, Sharma G, Lim HS, et al. Long-term mechanical consequences of permanent right ventricular pacing: effect of pacing site. J Cardiovasc Electrophysiol. 2010;21(10):1120–6. doi: 10.1111/j.1540-8167.2010.01804.x. [pii]: JCE1804.PubMedGoogle Scholar
  158. 158.
    Tse HF, Lau CP. Long-term effect of right ventricular pacing on myocardial perfusion and function. J Am Coll Cardiol. 1997;29(4):744–9. [pii]: S0735109796005864.PubMedGoogle Scholar
  159. 159.
    Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16(11):1160–5. doi: 10.1111/j.1540-8167.2005.50062.x. [pii]: JCE50062.PubMedGoogle Scholar
  160. 160.
    Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein isolation for atrial fibrillation in patients with HF. N Engl J Med. 2008;359(17):1778–85.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Cardiac ElectrophysiologyBrigham and Women’s Hospital/HarvardNewtonUSA
  2. 2.2C2 W.C. Mackenzie Health Sciences Centre, Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart InstituteUniversity of Alberta and HospitalsEdmontonCanada

Personalised recommendations